ArticleGenes2022
Genetic Association between ACE2 (rs2285666 and rs2074192) and TMPRSS2 (rs12329760 and rs2070788) Polymorphisms with Post-COVID Symptoms in Previously Hospitalized COVID-19 Survivors.
Article in Genes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 33 citations in OpenAlex.
- Genetic association between LONG COVID and TMPRSS2 polymorphisms (rs12329760 and rs2070788) in Brazilian healthcare professionals.Frontiers in cellular and infection microbiology · 2026Article
- Influence of inflammatory and reninangiotensin system gene polymorphisms ACE2 rs2285666, IL1A rs1800587, and TNF rs1800629 on COVID-19 severity and the persistence of symptoms in the post-COVID-19 phase: a cross-sectional study.Einstein (Sao Paulo, Brazil) · 2026Article
- DNA Salivary Methylation Levels of the ACE2 Promoter Are Not Related to ACE2 (International journal of molecular sciences · 2025Article
- Genetics of Long COVID: Exploring the Molecular Drivers of Persistent Pulmonary Vascular Disease Symptoms.Infectious disease reports · 2025Review
- Screening Biomarkers and Risk Factors for COVID-19 Progression in a Border Population Between Brazil-Bolivia.Biomedical engineering and computational biology · 2025Article
- Comparative cohort study of post-acute COVID-19 infection with a nested, randomized controlled trial of ivabradine for those with postural orthostatic tachycardia syndrome (the COVIVA study).Frontiers in neurology · 2025Article
- Genetic variants inFrontiers in genetics · 2025Article
- Article
- Inflammatory Polymorphisms (IL-6Viruses · 2024Article
- Long COVID and its association with neurodegenerative diseases: pathogenesis, neuroimaging, and treatment.Frontiers in neurology · 2024Review
- Association betweenFrontiers in medicine · 2024Article
- Role ofAfrican journal of laboratory medicine · 2024Article
- Long COVID or Post-COVID-19 Condition: Past, Present and Future Research Directions.Microorganisms · 2023Review
- Mechanisms of long COVID: An updated review.Chinese medical journal pulmonary and critical care medicine · 2023Review
- Predictive Factors andInternational journal of molecular sciences · 2023Article
- The Relationship between COVID-19 Severity in Children and Immunoregulatory Gene Polymorphism.Viruses · 2023Article
- Article
- Genetic Predictors of Comorbid Course of COVID-19 and MAFLD: A Comprehensive Analysis.Viruses · 2023Review
- Article
- Pathogenesis Underlying Neurological Manifestations of Long COVID Syndrome and Potential Therapeutics.Cells · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the study was to identify the association between four selected COVID-19 polymorphisms of ACE2 and TMPRSS2 receptors genes with the presence of long-COVID symptomatology in COVID-19 survivors. These genes were selected as they associate with the entry of the SARS-CoV-2 virus into the cells, so polymorphisms could be important for the prognoses of long-COVID symptoms. Two hundred and ninety-three (n = 293, 49.5% female, mean age: 55.6 ± 12.9 years) individuals who had been previously hospitalized due to COVID-19 were included. Three potential genotypes of the following single nucleotide polymorphisms (SNPs) were obtained from non-stimulated saliva samples of participants: ACE2 (rs2285666), ACE2 (rs2074192), TMPRSS2 (rs12329760), TMPRSS2 (rs2070788). Participants were asked to self-report the presence of any post-COVID defined as a symptom that started no later than one month after SARS-CoV-2 acute infection and whether the symptom persisted at the time of the study. At the time of the study (mean: 17.8, SD: 5.2 months after hospital discharge), 87.7% patients reported at least one symptom. Fatigue (62.8%), pain (39.9%) or memory loss (32.1%) were the most prevalent post-COVID symptoms. Overall, no differences in long-COVID symptoms were dependent on ACE2 rs2285666, ACE2 rs2074192, TMPRSS2 rs12329760, or TMPRSS2 rs2070788 genotypes. The four SNPs assessed, albeit previously associated with COVID-19 severity, do not predispose for developing long-COVID symptoms in people who were previously hospitalized due to COVID-19 during the first wave of the pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.